These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32773243)

  • 1. Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus.
    Dayan GH; Langevin E; Forrat R; Zambrano B; Noriega F; Frago C; Bouckenooghe A; Machabert T; Savarino S; DiazGranados CA
    Vaccine; 2020 Sep; 38(41):6472-6477. PubMed ID: 32773243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus.
    Dayan GH; Langevin E; Gilbert PB; Wu Y; Moodie Z; Forrat R; Price B; Frago C; Bouckenooghe A; Cortes M; Noriega F; DiazGranados CA
    Vaccine; 2020 Apr; 38(19):3531-3536. PubMed ID: 32204943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America.
    Forrat R; Dayan GH; DiazGranados CA; Bonaparte M; Laot T; Capeding MR; Sanchez L; Coronel DL; Reynales H; Chansinghakul D; Hadinegoro SRS; Perroud AP; Frago C; Zambrano B; Machabert T; Wu Y; Luedtke A; Price B; Vigne C; Haney O; Savarino SJ; Bouckenooghe A; Noriega F
    Clin Infect Dis; 2021 Sep; 73(6):1003-1012. PubMed ID: 33822015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
    Coronel-MartÍnez DL; Park J; López-Medina E; Capeding MR; Cadena Bonfanti AA; Montalbán MC; Ramírez I; Gonzales MLA; DiazGranados CA; Zambrano B; Dayan G; Savarino S; Chen Z; Wang H; Sun S; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
    Lancet Infect Dis; 2021 Apr; 21(4):517-528. PubMed ID: 33212067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy.
    Sridhar S; Luedtke A; Langevin E; Zhu M; Bonaparte M; Machabert T; Savarino S; Zambrano B; Moureau A; Khromava A; Moodie Z; Westling T; Mascareñas C; Frago C; Cortés M; Chansinghakul D; Noriega F; Bouckenooghe A; Chen J; Ng SP; Gilbert PB; Gurunathan S; DiazGranados CA
    N Engl J Med; 2018 Jul; 379(4):327-340. PubMed ID: 29897841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials.
    Tran NH; Chansinghakul D; Chong CY; Low CY; Shek LP; Luong CQ; Fargo C; Wartel TA; Sun S; Skipetrova A; Bouckenooghe A
    Hum Vaccin Immunother; 2019; 15(10):2315-2327. PubMed ID: 30724660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Response Persistence and Safety of a Booster Dose of the Tetravalent Dengue Vaccine in Adolescents and Adults Who Previously Completed the 3-dose Schedule 4-5 Years Earlier in Latin America: A Randomized Placebo-controlled Trial.
    Coronel D; García-Rivera EJ; Rivera DM; Arredondo-García JL; Dietze R; Perroud AP; Cortés M; Bonaparte M; Wang H; Pagnon A; Jantet-Blaudez F; Peñalosa LAR; Dayan G; Zambrano B; DiazGranados CA; Noriega F
    Pediatr Infect Dis J; 2020 Oct; 39(10):961-968. PubMed ID: 32932330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
    Dubey AP; Agarkhedkar S; Chhatwal J; Narayan A; Ganguly S; Wartel TA; Bouckenooghe A; Menezes J
    Hum Vaccin Immunother; 2016; 12(2):512-8. PubMed ID: 26291554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.
    Kirstein J; Douglas W; Thakur M; Boaz M; Papa T; Skipetrova A; Plennevaux E
    BMC Infect Dis; 2018 Sep; 18(1):475. PubMed ID: 30241510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials.
    DiazGranados CA; Bonaparte M; Wang H; Zhu M; Lustig Y; Schwartz E; Forrat R; Dayan GH; Hodge S; Ataman-Önal Y; Savarino SJ
    Lancet Infect Dis; 2021 Apr; 21(4):529-536. PubMed ID: 33212068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countries.
    Huang Y; Moodie Z; Juraska M; Fong Y; Carpp LN; Chambonneau L; Coronel DL; Dayan GH; DiazGranados CA; Gilbert PB
    Trans R Soc Trop Med Hyg; 2021 Jul; 115(7):750-763. PubMed ID: 33369671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia.
    Reynales H; Carrasquilla G; Zambrano B; Cortés S M; Machabert T; Jing J; Pallardy S; Haney O; Faccini M; Quintero J; Noriega F
    Pediatr Infect Dis J; 2020 Apr; 39(4):e30-e36. PubMed ID: 32040014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination.
    Vigne C; Dupuy M; Richetin A; Guy B; Jackson N; Bonaparte M; Hu B; Saville M; Chansinghakul D; Noriega F; Plennevaux E
    Hum Vaccin Immunother; 2017 Sep; 13(9):2004-2016. PubMed ID: 28598256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
    Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with a new dengue rapid diagnostic test: a retrospective analysis of phase 3 efficacy trials.
    Savarino SJ; Bonaparte M; Wang H; Dayan GH; Forrat R; Zhu M; Hodge S; Ataman-Önal Y; DiazGranados CA
    Lancet Microbe; 2022 Jun; 3(6):e427-e434. PubMed ID: 35659904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response.
    Gilbert PB; Huang Y; Juraska M; Moodie Z; Fong Y; Luedtke A; Zhuang Y; Shao J; Carpp LN; Jackson N; Chambonneau L; Bouckenooghe A; Zambrano B; Frago C; Pallardy S; Noriega F
    Am J Trop Med Hyg; 2019 Jul; 101(1):164-179. PubMed ID: 31115304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5-6 years after completion of the primary series.
    Park J; Archuleta S; Oh MH; Shek LP; Jin J; Bonaparte M; Fargo C; Bouckenooghe A
    Hum Vaccin Immunother; 2020 Mar; 16(3):523-529. PubMed ID: 31464558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals.
    DiazGranados CA; Langevin E; Bonaparte M; Sridhar S; Machabert T; Dayan G; Forrat R; Savarino S
    Clin Infect Dis; 2021 May; 72(10):1730-1737. PubMed ID: 32198515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America.
    Villar LÁ; Rivera-Medina DM; Arredondo-García JL; Boaz M; Starr-Spires L; Thakur M; Zambrano B; Miranda MC; Rivas E; Dayan GH
    Pediatr Infect Dis J; 2013 Oct; 32(10):1102-9. PubMed ID: 24067553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9-50 years: a randomised, controlled, phase 2, non-inferiority study.
    Coronel-Martinez DL; Park J; López-Medina E; Capeding MR; Bonfanti AAC; Montalbán MC; Ramírez I; Gonzales MLA; Zambrano B; Dayan G; Chen Z; Wang H; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
    Lancet Infect Dis; 2022 Jun; 22(6):901-911. PubMed ID: 35364022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.